Status: Recruiting
Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM
This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of Candonilimab (AK104) combined with Regorafenib for the treatment of MSS colorectal liver metastasis. Candonilimab (AK104) is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.
Participants needed: 44
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Jin-hong ChenUpdated: Jul 30, 2024Locations: 3
Eligibility criteria
Age > 18 years old and < 75 years old; [+9]
Women who are pregnant or breastfeeding; [+10]